Detalhe da pesquisa
1.
Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index.
Am J Hematol
; 95(8): 906-917, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32279347
2.
Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis.
Blood Adv
; 8(9): 2118-2129, 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38359367
3.
Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL.
Blood Adv
; 7(13): 3169-3179, 2023 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36877634
4.
Transcriptional profiles define drug refractory disease in myeloma.
EJHaem
; 3(3): 804-814, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36051067
5.
Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity.
Mol Cancer Res
; 18(10): 1453-1464, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32561655
6.
"Direct to Drug" screening as a precision medicine tool in multiple myeloma.
Blood Cancer J
; 10(5): 54, 2020 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32393731
7.
Canine mammary mixed tumours: a review.
Vet Med Int
; 2012: 274608, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23193497